The process of developing and bringing new medicines to patients in need is oftentimes lengthy and complex, which is why anything that can be done to expedite this process is critical for patients who are waiting for new treatment options. In the case of B6A, Seagen’s investigational antibody-drug conjugate (ADC), we focused on shortening the amount of time from receiving investigational new drug (IND) clearance to enrolling the first patient in a clinical study. As a result of cross-functional collaboration, commitment to urgency, and solution orientation, Seagen was able to stand up the first first-in-human B6A clinical study in record time – setting a new bar for Seagen’s future early clinical trials.